Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
02 2020
Historique:
received: 15 05 2019
revised: 08 08 2019
accepted: 22 11 2019
pubmed: 4 12 2019
medline: 20 1 2021
entrez: 4 12 2019
Statut: ppublish

Résumé

Tobacco smoking and alcohol consumption have been intensively studied in the general population to assess their effects on the risk of breast cancer, but very few studies have examined these effects in Using a large international pooled cohort of For both The finding that smoking during the prereproductive years increases breast cancer risk for mutation carriers warrants further investigation. This is the largest prospective study of

Sections du résumé

BACKGROUND
Tobacco smoking and alcohol consumption have been intensively studied in the general population to assess their effects on the risk of breast cancer, but very few studies have examined these effects in
METHODS
Using a large international pooled cohort of
RESULTS
For both
CONCLUSIONS
The finding that smoking during the prereproductive years increases breast cancer risk for mutation carriers warrants further investigation.
IMPACT
This is the largest prospective study of

Identifiants

pubmed: 31792088
pii: 1055-9965.EPI-19-0546
doi: 10.1158/1055-9965.EPI-19-0546
pmc: PMC7611162
mid: EMS128692
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

368-378

Subventions

Organisme : Cancer Research UK
ID : A10118
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A11174
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A20861
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C12292/A20861
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA159868
Pays : United States
Organisme : Cancer Research UK
ID : 10118
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1287/A11990
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C12292/A11174
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A11990
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA164920
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

J Natl Cancer Inst Monogr. 2011;2011(43):79-81
pubmed: 22043047
Genet Epidemiol. 2005 Jul;29(1):1-11
pubmed: 15880399
JNCI Cancer Spectr. 2018 Dec;2(4):pky078
pubmed: 30873510
Breast Cancer Res Treat. 2006 Aug;98(3):285-94
pubmed: 16541324
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Cancer Causes Control. 2001 Dec;12(10):895-902
pubmed: 11808708
J Natl Cancer Inst. 2013 Apr 17;105(8):515-25
pubmed: 23449445
Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):32-41
pubmed: 23150063
Cell. 2017 Jun 1;169(6):1105-1118.e15
pubmed: 28575672
J Natl Cancer Inst. 1978 Dec;61(6):1451-9
pubmed: 102857
Breast Cancer Res Treat. 2010 Nov;124(2):441-51
pubmed: 20309627
Breast Cancer Res Treat. 2008 May;109(1):67-75
pubmed: 17972172
J Natl Cancer Inst. 2009 Mar 4;101(5):296-305
pubmed: 19244173
Cancer Epidemiol. 2014 Aug;38(4):419-26
pubmed: 24950597
JAMA. 2011 Nov 2;306(17):1884-90
pubmed: 22045766
Ann Epidemiol. 2006 Mar;16(3):230-40
pubmed: 16230024
Breast Cancer Res. 2004;6(4):R375-89
pubmed: 15217505
Int J Epidemiol. 2017 Jun 1;46(3):881-893
pubmed: 28031315
Breast Cancer Res Treat. 1982;2(1):5-73
pubmed: 6216933
Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1565-7
pubmed: 16896052
Int J Cancer. 2004 Jun 20;110(3):413-6
pubmed: 15095307
Breast Cancer Res Treat. 2006 Jan;95(2):105-9
pubmed: 16261399
Breast. 2010 Dec;19(6):479-83
pubmed: 20541936
Int J Epidemiol. 2016 Jun;45(3):683-92
pubmed: 26174520
J Natl Cancer Inst. 2013 Oct 16;105(20):1571-8
pubmed: 23985142
J Natl Cancer Inst. 1998 May 20;90(10):761-6
pubmed: 9605646
J Natl Cancer Inst. 2014 Jun;106(6):dju091
pubmed: 24824314
Carcinogenesis. 2006 Mar;27(3):599-605
pubmed: 16244359
Breast Cancer Res Treat. 2009 Mar;114(1):127-35
pubmed: 18483851
Fam Cancer. 2005;4(2):105-13
pubmed: 15951960
Br J Cancer. 2002 Nov 18;87(11):1234-45
pubmed: 12439712

Auteurs

Hongyan Li (H)

Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.

Mary Beth Terry (MB)

Department of Epidemiology, Columbia University, New York, New York.
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.

Antonis C Antoniou (AC)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom.

Kelly-Anne Phillips (KA)

Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Victoria, Australia.
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Karin Kast (K)

Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany.
German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Thea M Mooij (TM)

Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Christoph Engel (C)

Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany.

Catherine Noguès (C)

Institut Paoli-Calmettes, Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique and Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.

Dominique Stoppa-Lyonnet (D)

Institut Curie, Service de Génétique Médicale, Paris, France.
Inserm, U830, Université Paris Descartes, Paris, France.

Christine Lasset (C)

Unité de prévention et Epidémiologie Génétique, Centre Léon Bérard - Lyon/UMR CNRS 5558, Université de Lyon - Lyon, France.

Pascaline Berthet (P)

Département de biopathologie, Oncogénétique clinique, Centre François Baclesse - Caen, France.

Veronique Mari (V)

CLCC Antoine Lacassagne, Département d'Hématologie - Oncologie médicale, Nice, France.

Olivier Caron (O)

Département de Médecine, Gustave Roussy Hôpital Universitaire - Villejuif, France.

Daniel Barrowdale (D)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom.

Debra Frost (D)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom.

Carole Brewer (C)

Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, United Kingdom.

D Gareth Evans (DG)

Genomic Medicine, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, Manchester University, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.

Louise Izatt (L)

Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.

Lucy Side (L)

Wessex Clinical Genetics Service, The Princess Anne Hospital, Southampton, United Kingdom.

Lisa Walker (L)

Oxford Regional Genetics Service, Churchill Hospital, Oxford, United Kingdom.

Marc Tischkowitz (M)

University of Cambridge Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, and Cancer Research UK Cambridge Center, Cambridge Biomedical Campus, Cambridge, United Kingdom.

Mark T Rogers (MT)

All Wales Medical Genetics Services, University Hospital of Wales, Cardiff, United Kingdom.

Mary E Porteous (ME)

South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, United Kingdom.

Katie Snape (K)

Medical Genetics Unit, St. George's, University of London, London, United Kingdom.

Hanne E J Meijers-Heijboer (HEJ)

Department of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands.

Johan J P Gille (JJP)

Department of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands.

Marinus J Blok (MJ)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands.

Nicoline Hoogerbrugge (N)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Mary B Daly (MB)

Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Irene L Andrulis (IL)

Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.

Saundra S Buys (SS)

Department of Medicine, University of Utah Health Sciences Center, Huntsman Cancer Institute, Salt Lake City, Utah.

Esther M John (EM)

Stanford University School of Medicine, Department of Medicine, Division of Oncology, and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.

Sue-Anne McLachlan (SA)

Department of Medicine, St. Vincent's Hospital, The University of Melbourne, Parkville, Victoria, Australia.
Department of Medical Oncology, St. Vincent's Hospital, Fitzroy, Victoria, Australia.

Michael Friedlander (M)

Department of Medical Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Yen Y Tan (YY)

Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Ana Osorio (A)

Human Genetics Group, Spanish National Cancer Centre (CNIO) and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.

Trinidad Caldes (T)

Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, CIBERONC (ISCIII), Madrid, Spain.

Anna Jakubowska (A)

Department of Genetics and Pathology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, Poland.
Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.

Jacques Simard (J)

Genomics Center, Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Quebec City, Quebec, Canada.

Christian F Singer (CF)

Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Edith Olah (E)

Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.

Marie Navratilova (M)

Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, Czech Republic.

Lenka Foretova (L)

Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, Czech Republic.

Anne-Marie Gerdes (AM)

The Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.

Marie-José Roos-Blom (MJ)

Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Brita Arver (B)

Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Department of Oncology, Lund University Hospital, Lund, Sweden.

Håkan Olsson (H)

Department of Oncology, Lund University Hospital, Lund, Sweden.

Rita K Schmutzler (RK)

Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.
Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.

John L Hopper (JL)

Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Victoria, Australia.

Roger L Milne (RL)

Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Victoria, Australia.
Division of Cancer Epidemiology and Intelligence, Cancer Council Victoria, Melbourne, Australia.
Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.

Douglas F Easton (DF)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom.
Centre for Cancer Genetic Epidemiology, Department of Oncology, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom.

Flora E Van Leeuwen (FE)

Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Matti A Rookus (MA)

Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Nadine Andrieu (N)

INSERM, U900, Paris, France. david.goldgar@hsc.utah.edu nadine.andrieu@curie.fr.
Institut Curie, Paris, France.
Mines Paris Tech, Fontainebleau, France.
PSL Research University, Paris, France.

David E Goldgar (DE)

Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah. david.goldgar@hsc.utah.edu nadine.andrieu@curie.fr.
Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH